SCHEMBL6350098

SCHEMBL6350098

CC(C)C(C(N)=O)N(CC(=O)c1ccccc1)C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
TRPM8 Q7Z2W7 3/20 0.38
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 3/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
USP2 O75604 1/20 0.37
MAPT P10636 3/20 0.35
AGTR1 P30556 1/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
ALOX15 P16050 1/20 0.35
CES1 P23141 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352444 0.89 TSHR (0.41) TSHRKMT2ASMN1; SMN2MEN1CYP3A4
SCHEMBL6359179 0.85 TRPM8 (0.47) TRPM8KMT2ASMN1; SMN2MEN1CYP3A4
SCHEMBL6354208 0.85 ALDH1A1 (0.43) TSHRTRPM8KMT2ASMN1; SMN2MEN1
SCHEMBL6347733 0.85 ALDH1A1 (0.43) TSHRTRPM8KMT2ASMN1; SMN2MEN1
SCHEMBL6347856 0.85 ALDH1A1 (0.43) TSHRTRPM8KMT2ASMN1; SMN2MEN1
SCHEMBL6350864 0.85 TRPM8 (0.47) TRPM8KMT2ASMN1; SMN2MEN1CYP3A4
SCHEMBL6350601 0.81 KMT2A (0.42) TSHRTRPM8KMT2ASMN1; SMN2MEN1
SCHEMBL6350685 0.79 KMT2A (0.38) TSHRTRPM8KMT2ASMN1; SMN2MEN1
SCHEMBL6357950 0.79 ALDH1A1 (0.48) TRPM8KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL6359360 0.79 KMT2A (0.38) TSHRTRPM8KMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 TSHR 338/4885TRPM8 1934/4885KMT2A 3612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.